Cogent Biosciences: Time For A Pause [Seeking Alpha]
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)